Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.

For investors eyeing Biocon’s stock, this approval could be a significant catalyst. According to InvestingPro’s fair value ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

U.S. President Donald Trump said on Tuesday he intends to impose a "25% or higher" levies on semiconductors and ...

Donald Trump's proposal to impose a 25% or more tariff on pharmaceutical imports into the United States holds significant ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Shaw, Founder and Executive Chairperson of Biocon, on catching up with China, the right recruitment policies, and more.

India’s biotech sector works on tech, talent pool & advanced production plants to align with Viksit Bharat: Nandita Vijayasimha, Bengaluru Wednesday, February 19, 2025, 08:00 Hr ...

Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

Fulphila was co-developed through a collaboration between Mylan and India’s Biocon that has produced 11 biologic and insulin products, including the FDA-approved Ogivri, a biosimilar version of ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...